Eagan-based Pelvital raised an additional $2.32 million in its seed-plus funding round, bringing the total effort to $5 million
The company closed the first half of this round in 2023, raising $2.68 million.
Boomerang Ventures led the investment round and Pier 70 Ventures, Life Science Angels, Tech Coast Angels Orange County and Blue Pacific Fund participated.
The women's health-focused medical device company will use the funding to expedite the commercialization of its medical device Flyte, developing a next-generation device, expanding market access, insurance coverage for the device and clinician awareness, said Lydia Zeller, CEO and president of Pelvital.
The device is a nonsurgical bladder-leak treatment for stress urinary incontinence and weakened pelvic floor muscles. Patients use the device five minutes a day, six days a week to help strengthen pelvic floor muscles and neuromuscular memory.
"It's an underserved area, and 62% of women have urinary incontinence and it's untreated," Zeller said. "It's a huge need. There's a lack of research, funding and focus in this area."
Flyte was developed by researchers and physicians at the Arctic University of Norway and other experts in gynecology, muscle rehabilitation and urinary incontinence treatments. The product has undergone two clinical trials and was FDA-cleared in 2020.
The company has grown in revenue and employees in the past year, with a total of seven full-time positions. In this upcoming year the company will focus on advocacy for screening for urinary incontinence at primary care physicians and OB/GYN offices.
Pelvital was founded in 2016 by researchers at Arctic University in Norway and former Medtronic executive Dale Wahlstrom.
